Comparison · NCT00779402-a082ac5b
Sipuleucel-T vs Control: Number of Subjects That Met Biochemical Failure Status
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Sipuleucel-T vs Control: Number of Subjects That Met Biochemical Failure Status. Trial comparisons, record NCT00779402-a082ac5b. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00779402-a082ac5b
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.726 | 0.639 | 0.799 | wilson | |
| Risk in group 2 | 0.763 | 0.64 | 0.853 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0362 | -0.162 | 0.106 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.953 | 0.795 | 1.14 | log | |
| Odds ratio, group 1 over group 2 | 0.826 | 0.4 | 1.71 | log | |
| Number needed to treat, for one fewer participant with the outcome on Sipuleucel-T than on Control | 27.6 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: control.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Sipuleucel-T | Subjects received infusion of Sipuleucel-T, at 2-week intervals, for a total of 3 infusions. | 85 | 117 | OG000 |
| Group 2 | Control | Subjects received infusion of control (autologous cellular product consisting of antigen presenting cells (APCs) prepared in the absence of PA2024 antigen) at 2-week intervals, for a total of 3 infusions. | 45 | 59 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of Subjects That Met Biochemical Failure Status
- Description
time to biochemical Failure (TTBF) was the pre-scpecified primary endpoint of this trial. The biochemical failure threshold was based on evidence that prostate specific antigen (PSA) had become ≥ 3 ng/mL.
- Time frame
- Every 3 months post-infusion
- Population
Source ClinicalTrials.gov
Trial
- Title
- PROvenge Treatment and Early Cancer Treatment
- NCT number
- NCT00779402
- Phases
- PHASE3
- Conditions
- Prostate Cancer
- Interventions
- Control, Sipuleucel-T
- Lead sponsor
- Dendreon
- Results first posted
- 2018-01-29
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00779402?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00779402-a082ac5b